Arsenic trioxide and olanzapine co-administration: case analysis.

Abstract

QTc prolongation is associated with arsenic trioxide (ATO) treatment of acute promyelocytic leukemia (APL). Olanzapine was safely co-administered with ATO to treat co-morbid psychiatric diagnoses. It is important to closely monitor for drug-drug interactions and cumulative drug adverse effects in patients receiving oncology agents and psychotropics. Further… (More)
DOI: 10.1177/1078155209352912

Topics

Cite this paper

@article{Kaufman2011ArsenicTA, title={Arsenic trioxide and olanzapine co-administration: case analysis.}, author={Kenneth R. Kaufman and Saurabh Chhabra and Michael Levitt and Rahul N Sood}, journal={Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners}, year={2011}, volume={17 3}, pages={260-4} }